Skip to main content
Top
Published in: Pediatric Radiology 4/2018

01-04-2018 | Review

Role of interventional radiology in managing pediatric liver tumors

Part 1: Endovascular interventions

Authors: Matthew P. Lungren, Alexander J. Towbin, Derek J. Roebuck, Eric J. Monroe, Anne E. Gill, Avnesh Thakor, Richard B. Towbin, Anne Marie Cahill, C. Matthew Hawkins

Published in: Pediatric Radiology | Issue 4/2018

Login to get access

Abstract

Primary liver malignancies are rare in children. Hepatoblastoma and hepatocellular carcinoma (HCC) together represent the overwhelming majority of cases. Overall survival of hepatoblastoma approaches 80% with multimodal treatment approaches that include chemotherapy, surgery and transplantation. However, there remains a subset of children with hepatoblastoma in whom resection or transplantation is not possible. The 5-year survival for children diagnosed with HCC is less than 30% and remains a significant therapeutic challenge. The poor outcomes for children with primary liver tumors motivate investigation of new therapeutic alternatives. Interventional oncology offers a broad scope of percutaneous and transcatheter endovascular cancer therapies that might provide clinical benefits. Minimally invasive approaches are distinct from medical, surgical and radiation oncologic treatments, and in adults these approaches have been established as the fourth pillar of cancer care. Transarterial chemoembolization is a minimally invasive locoregional treatment option performed by interventional radiologists with level-I evidence as standard of care in adults with advanced liver malignancy; transarterial chemoembolization in adults has served to prolong disease-free progression, downstage and bridge patients for surgical and transplant interventions, and improve overall survival. However, while several groups have reported that transarterial chemoembolization is feasible in children, the published experience is limited primarily to small retrospective case series. The lack of prospective trial evidence has in part limited the utilization of transarterial chemoembolization in the pediatric patient population. The purpose of this article is to provide an overview of the role of interventional radiology in the diagnosis and endovascular management of hepatic malignancies in children.
Literature
1.
go back to reference Llovet JM, Beaugrand M (2003) Hepatocellular carcinoma: present status and future prospects. J Hepatol 38:S136–S149CrossRefPubMed Llovet JM, Beaugrand M (2003) Hepatocellular carcinoma: present status and future prospects. J Hepatol 38:S136–S149CrossRefPubMed
2.
go back to reference Marsh JW, Geller DA, Finkelstein SD et al (2004) Role of liver transplantation for hepatobiliary malignant disorders. Lancet Oncol 5:480–488CrossRefPubMed Marsh JW, Geller DA, Finkelstein SD et al (2004) Role of liver transplantation for hepatobiliary malignant disorders. Lancet Oncol 5:480–488CrossRefPubMed
3.
go back to reference Katzenstein HM, Krailo MD, Malogolowkin MH et al (2002) Hepatocellular carcinoma in children and adolescents: results from the pediatric oncology group and the Children's cancer group intergroup study. J Clin Oncol 20:2789–2797CrossRefPubMed Katzenstein HM, Krailo MD, Malogolowkin MH et al (2002) Hepatocellular carcinoma in children and adolescents: results from the pediatric oncology group and the Children's cancer group intergroup study. J Clin Oncol 20:2789–2797CrossRefPubMed
4.
go back to reference Cruz RJ Jr, Ranganathan S, Mazariegos G et al (2013) Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: new trends and future opportunities. Surgery 153:150–159CrossRefPubMed Cruz RJ Jr, Ranganathan S, Mazariegos G et al (2013) Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: new trends and future opportunities. Surgery 153:150–159CrossRefPubMed
5.
go back to reference Ismail H, Broniszczak D, Kalicinski P et al (2009) Liver transplantation in children with hepatocellular carcinoma. Do Milan criteria apply to pediatric patients? Pediatr Transplant 13:682–692CrossRefPubMed Ismail H, Broniszczak D, Kalicinski P et al (2009) Liver transplantation in children with hepatocellular carcinoma. Do Milan criteria apply to pediatric patients? Pediatr Transplant 13:682–692CrossRefPubMed
6.
go back to reference Kalicinski PJ, Ismail H, Broniszczak D et al (2014) Primary malignant hepatic tumors as indication for liver transplantation in children — 20 years experience. Liver Transplant 20:S259 Kalicinski PJ, Ismail H, Broniszczak D et al (2014) Primary malignant hepatic tumors as indication for liver transplantation in children — 20 years experience. Liver Transplant 20:S259
7.
go back to reference Beaunoyer M, Vanatta JM, Ogihara M et al (2007) Outcomes of transplantation in children with primary hepatic malignancy. Pediatr Transplant 11:655–660CrossRefPubMed Beaunoyer M, Vanatta JM, Ogihara M et al (2007) Outcomes of transplantation in children with primary hepatic malignancy. Pediatr Transplant 11:655–660CrossRefPubMed
8.
go back to reference Depotter CR, Robberecht E, Laureys G et al (1987) Hepatitis-B related childhood hepatocellular-carcinoma — childhood hepatic malignancies. Cancer 60:414–418CrossRef Depotter CR, Robberecht E, Laureys G et al (1987) Hepatitis-B related childhood hepatocellular-carcinoma — childhood hepatic malignancies. Cancer 60:414–418CrossRef
9.
go back to reference Czauderna P (2002) Adult type vs. childhood hepatocellular carcinoma — are they the same or different lesions? Biology, natural history, prognosis, and treatment. Med Pediatr Oncol 39:519–523CrossRefPubMed Czauderna P (2002) Adult type vs. childhood hepatocellular carcinoma — are they the same or different lesions? Biology, natural history, prognosis, and treatment. Med Pediatr Oncol 39:519–523CrossRefPubMed
10.
go back to reference Allan BJ, Wang B, Davis JS et al (2014) A review of 218 pediatric cases of hepatocellular carcinoma. J Pediatr Surg 49:166–171CrossRefPubMed Allan BJ, Wang B, Davis JS et al (2014) A review of 218 pediatric cases of hepatocellular carcinoma. J Pediatr Surg 49:166–171CrossRefPubMed
11.
go back to reference Kim H, Lee MJ, Kim MR et al (2000) Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: comparison study of childhood and adult hepatocellular carcinoma. Liver 20:173–178CrossRefPubMed Kim H, Lee MJ, Kim MR et al (2000) Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: comparison study of childhood and adult hepatocellular carcinoma. Liver 20:173–178CrossRefPubMed
12.
go back to reference Torbenson MS (2017) Morphologic subtypes of hepatocellular carcinoma. Gastroenterol Clin N Am 46:365–391CrossRef Torbenson MS (2017) Morphologic subtypes of hepatocellular carcinoma. Gastroenterol Clin N Am 46:365–391CrossRef
13.
go back to reference Meyers AB, Towbin AJ, Geller JI et al (2012) Hepatoblastoma imaging with gadoxetate disodium-enhanced MRI — typical, atypical, pre- and post-treatment evaluation. Pediatr Radiol 42:859–866CrossRefPubMed Meyers AB, Towbin AJ, Geller JI et al (2012) Hepatoblastoma imaging with gadoxetate disodium-enhanced MRI — typical, atypical, pre- and post-treatment evaluation. Pediatr Radiol 42:859–866CrossRefPubMed
14.
go back to reference Pugmire BS, Towbin AJ (2016) Magnetic resonance imaging of primary pediatric liver tumors. Pediatr Radiol 46:764–777CrossRefPubMed Pugmire BS, Towbin AJ (2016) Magnetic resonance imaging of primary pediatric liver tumors. Pediatr Radiol 46:764–777CrossRefPubMed
15.
go back to reference Roebuck DJ, Aronson D, Clapuyt P et al (2007) 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol 37:123–132CrossRefPubMed Roebuck DJ, Aronson D, Clapuyt P et al (2007) 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol 37:123–132CrossRefPubMed
16.
go back to reference Fuchs J, Cavdar S, Blumenstock G et al (2016) POST-TEXT III and IV hepatoblastoma: extended hepatic resection avoids liver transplantation in selected cases. Ann Surg 266:318–323CrossRef Fuchs J, Cavdar S, Blumenstock G et al (2016) POST-TEXT III and IV hepatoblastoma: extended hepatic resection avoids liver transplantation in selected cases. Ann Surg 266:318–323CrossRef
17.
go back to reference La Quaglia MP (2014) State of the art in oncology: high risk neuroblastoma, alveolar rhabdomyosarcoma, desmoplastic small round cell tumor, and POST-TEXT 3 and 4 hepatoblastoma. J Pediatr Surg 49:233–240CrossRefPubMed La Quaglia MP (2014) State of the art in oncology: high risk neuroblastoma, alveolar rhabdomyosarcoma, desmoplastic small round cell tumor, and POST-TEXT 3 and 4 hepatoblastoma. J Pediatr Surg 49:233–240CrossRefPubMed
18.
go back to reference Lautz TB, Ben-Ami T, Tantemsapya N et al (2011) Successful nontransplant resection of POST-TEXT III and IV hepatoblastoma. Cancer 117:1976–1983CrossRefPubMed Lautz TB, Ben-Ami T, Tantemsapya N et al (2011) Successful nontransplant resection of POST-TEXT III and IV hepatoblastoma. Cancer 117:1976–1983CrossRefPubMed
19.
go back to reference Kelly D, Sharif K, Brown RM et al (2015) Hepatocellular carcinoma in children. Clin Liver Dis 19:433–447CrossRefPubMed Kelly D, Sharif K, Brown RM et al (2015) Hepatocellular carcinoma in children. Clin Liver Dis 19:433–447CrossRefPubMed
20.
go back to reference Murawski M, Weeda VB, Maibach R et al (2016) Hepatocellular carcinoma in children: does modified platinum- and doxorubicin-based chemotherapy increase tumor resectability and change outcome? Lessons learned from the SIOPEL 2 and 3 studies. J Clin Oncol 34:1050–1056CrossRefPubMed Murawski M, Weeda VB, Maibach R et al (2016) Hepatocellular carcinoma in children: does modified platinum- and doxorubicin-based chemotherapy increase tumor resectability and change outcome? Lessons learned from the SIOPEL 2 and 3 studies. J Clin Oncol 34:1050–1056CrossRefPubMed
21.
go back to reference Czauderna P, Mackinlay G, Perilongo G et al (2002) Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 20:2798–2804CrossRefPubMed Czauderna P, Mackinlay G, Perilongo G et al (2002) Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 20:2798–2804CrossRefPubMed
22.
go back to reference Pham TA, Gallo AM, Concepcion W et al (2015) Effect of liver transplant on long-term disease-free survival in children with hepatoblastoma and hepatocellular cancer. JAMA Surg 150:1150–1158CrossRefPubMed Pham TA, Gallo AM, Concepcion W et al (2015) Effect of liver transplant on long-term disease-free survival in children with hepatoblastoma and hepatocellular cancer. JAMA Surg 150:1150–1158CrossRefPubMed
23.
go back to reference Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed
24.
go back to reference Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the liver. J Hepatol 35:421–430CrossRefPubMed Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the liver. J Hepatol 35:421–430CrossRefPubMed
25.
go back to reference Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed
26.
go back to reference Forner A, Ayuso C, Varela M et al (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115:616–623CrossRefPubMed Forner A, Ayuso C, Varela M et al (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115:616–623CrossRefPubMed
27.
go back to reference Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236CrossRefPubMed Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236CrossRefPubMed
28.
go back to reference Llovet JM, Di Bisceglie AM, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711CrossRefPubMed Llovet JM, Di Bisceglie AM, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711CrossRefPubMed
29.
go back to reference Lencioni R, Montal R, Torres F et al (2017) Objective response by mRECIST as a predictor and potential surrogate end point of overall survival in advanced HCC. J Hepatol 66:1166–1172CrossRefPubMed Lencioni R, Montal R, Torres F et al (2017) Objective response by mRECIST as a predictor and potential surrogate end point of overall survival in advanced HCC. J Hepatol 66:1166–1172CrossRefPubMed
30.
go back to reference van As JW, van den Berg H, van Dalen EC (2016) Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database Syst Rev 2016:CD010181 van As JW, van den Berg H, van Dalen EC (2016) Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database Syst Rev 2016:CD010181
31.
go back to reference Freyer DR, Chen L, Krailo MD et al (2017) Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18:63–74CrossRefPubMed Freyer DR, Chen L, Krailo MD et al (2017) Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18:63–74CrossRefPubMed
32.
go back to reference Meyers RL, Maibach R, Hiyama E et al (2017) Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic Tumors International Collaboration. Lancet Oncol 18:122–131CrossRefPubMed Meyers RL, Maibach R, Hiyama E et al (2017) Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic Tumors International Collaboration. Lancet Oncol 18:122–131CrossRefPubMed
33.
go back to reference McAteer JP, Goldin AB, Healey PJ et al (2013) Surgical treatment of primary liver tumors in children: outcomes analysis of resection and transplantation in the SEER database. Pediatr Transplant 17:744–750CrossRefPubMed McAteer JP, Goldin AB, Healey PJ et al (2013) Surgical treatment of primary liver tumors in children: outcomes analysis of resection and transplantation in the SEER database. Pediatr Transplant 17:744–750CrossRefPubMed
34.
go back to reference Zsiros J, Brugieres L, Brock P et al (2013) Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol 14:834–842CrossRefPubMedPubMedCentral Zsiros J, Brugieres L, Brock P et al (2013) Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol 14:834–842CrossRefPubMedPubMedCentral
35.
go back to reference Zsiros J, Maibach R, Shafford E et al (2010) Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 28:2584–2590CrossRefPubMed Zsiros J, Maibach R, Shafford E et al (2010) Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 28:2584–2590CrossRefPubMed
36.
go back to reference Kalicinski P, Ismail H, Broniszczak D et al (2008) Non-resectable hepatic tumors in children — role of liver transplantation. Ann Transplant 13:37–41PubMed Kalicinski P, Ismail H, Broniszczak D et al (2008) Non-resectable hepatic tumors in children — role of liver transplantation. Ann Transplant 13:37–41PubMed
37.
go back to reference Otte JB, Meyers RL, de Ville de Goyet J (2013) Transplantation for liver tumors in children: time to (re)set the guidelines? Pediatr Transplant 17:710–712CrossRefPubMed Otte JB, Meyers RL, de Ville de Goyet J (2013) Transplantation for liver tumors in children: time to (re)set the guidelines? Pediatr Transplant 17:710–712CrossRefPubMed
38.
go back to reference Tannuri AC, Tannuri U, Gibelli NE et al (2009) Surgical treatment of hepatic tumors in children: lessons learned from liver transplantation. J Pediatr Surg 44:2083–2087CrossRefPubMed Tannuri AC, Tannuri U, Gibelli NE et al (2009) Surgical treatment of hepatic tumors in children: lessons learned from liver transplantation. J Pediatr Surg 44:2083–2087CrossRefPubMed
39.
go back to reference Ohtsuka Y, Matsunaga T, Yoshida H et al (2004) Optimal strategy of preoperative transcatheter arterial chemoembolization for hepatoblastoma. Surg Today 34:127–133CrossRefPubMed Ohtsuka Y, Matsunaga T, Yoshida H et al (2004) Optimal strategy of preoperative transcatheter arterial chemoembolization for hepatoblastoma. Surg Today 34:127–133CrossRefPubMed
40.
go back to reference Farhi DC, Odell CA, Shurin SB (1993) Myelodysplastic syndrome and acute myeloid leukemia after treatment for solid tumors of childhood. Am J Clin Pathol 100:270–275CrossRefPubMed Farhi DC, Odell CA, Shurin SB (1993) Myelodysplastic syndrome and acute myeloid leukemia after treatment for solid tumors of childhood. Am J Clin Pathol 100:270–275CrossRefPubMed
41.
go back to reference Moppett J, Oakhill A, Duncan AW (2001) Second malignancies in children: the usual suspects? Eur J Radiol 37:95–108CrossRefPubMed Moppett J, Oakhill A, Duncan AW (2001) Second malignancies in children: the usual suspects? Eur J Radiol 37:95–108CrossRefPubMed
43.
go back to reference Hickey R, Vouche M, Sze DY et al (2013) Cancer concepts and principles: primer for the interventional oncologist-part II. J Vasc Interv Radiol 24:1167–1188CrossRefPubMedPubMedCentral Hickey R, Vouche M, Sze DY et al (2013) Cancer concepts and principles: primer for the interventional oncologist-part II. J Vasc Interv Radiol 24:1167–1188CrossRefPubMedPubMedCentral
44.
go back to reference Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25CrossRefPubMed Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25CrossRefPubMed
45.
go back to reference Salem R, Lewandowski RJ, Mulcahy MF et al (2010) Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138:52–64CrossRefPubMed Salem R, Lewandowski RJ, Mulcahy MF et al (2010) Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138:52–64CrossRefPubMed
46.
go back to reference Temple M, Marshalleck FE (2014) Pediatric interventional radiology handbook of vascular and non-vascular interventions. Springer Science + Business Media, New York Temple M, Marshalleck FE (2014) Pediatric interventional radiology handbook of vascular and non-vascular interventions. Springer Science + Business Media, New York
47.
go back to reference Tsochatzis EA, Fatourou E, O'Beirne J et al (2014) Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol 20:3069–3077CrossRefPubMedPubMedCentral Tsochatzis EA, Fatourou E, O'Beirne J et al (2014) Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol 20:3069–3077CrossRefPubMedPubMedCentral
48.
go back to reference Tsochatzis E, Meyer T, Marelli L et al (2010) Which transarterial therapy is best for hepatocellular carcinoma? — the evidence to date. J Hepatol 53:588CrossRefPubMed Tsochatzis E, Meyer T, Marelli L et al (2010) Which transarterial therapy is best for hepatocellular carcinoma? — the evidence to date. J Hepatol 53:588CrossRefPubMed
49.
go back to reference Kishore S, Friedman T, Madoff DC (2017) Update on embolization therapies for hepatocellular carcinoma. Curr Oncol Rep 19:40CrossRefPubMed Kishore S, Friedman T, Madoff DC (2017) Update on embolization therapies for hepatocellular carcinoma. Curr Oncol Rep 19:40CrossRefPubMed
50.
go back to reference Czauderna P, Zbrzezniak G, Narozanski W et al (2006) Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children. Pediatr Blood Cancer 46:825–828CrossRefPubMed Czauderna P, Zbrzezniak G, Narozanski W et al (2006) Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children. Pediatr Blood Cancer 46:825–828CrossRefPubMed
51.
go back to reference Chung GE, Lee JH, Kim HY et al (2011) Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 258:627–634CrossRefPubMed Chung GE, Lee JH, Kim HY et al (2011) Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 258:627–634CrossRefPubMed
52.
go back to reference Xue TC, Xie XY, Zhang L et al (2013) Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol 13:60CrossRefPubMedPubMedCentral Xue TC, Xie XY, Zhang L et al (2013) Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol 13:60CrossRefPubMedPubMedCentral
53.
go back to reference Brown DB, Pilgram TK, Darcy MD et al (2005) Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 16:1661–1666CrossRefPubMed Brown DB, Pilgram TK, Darcy MD et al (2005) Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 16:1661–1666CrossRefPubMed
54.
go back to reference Yamada R, Sato M, Kawabata M et al (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148:397–401CrossRefPubMed Yamada R, Sato M, Kawabata M et al (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148:397–401CrossRefPubMed
55.
go back to reference Nakamura H, Hashimoto T, Oi H et al (1989) Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 170:783–786CrossRefPubMed Nakamura H, Hashimoto T, Oi H et al (1989) Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 170:783–786CrossRefPubMed
57.
go back to reference Xie ZB, Ma L, Wang XB et al (2014) Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. Tumour Biol 35:8451–8459CrossRefPubMed Xie ZB, Ma L, Wang XB et al (2014) Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. Tumour Biol 35:8451–8459CrossRefPubMed
58.
go back to reference Carr BI, Kondragunta V, Buch SC et al (2010) Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 116:1305–1314CrossRefPubMedPubMedCentral Carr BI, Kondragunta V, Buch SC et al (2010) Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 116:1305–1314CrossRefPubMedPubMedCentral
59.
go back to reference Tsochatzis E, Meyer T, O'Beirne J, Burroughs AK (2013) Transarterial chemoembolisation is not superior to embolisation alone: the recent European Association for the Study of the liver (EASL) — European Organization for Research and Treatment of cancer (EORTC) guidelines. Eur J Cancer 49:1509–1510CrossRefPubMed Tsochatzis E, Meyer T, O'Beirne J, Burroughs AK (2013) Transarterial chemoembolisation is not superior to embolisation alone: the recent European Association for the Study of the liver (EASL) — European Organization for Research and Treatment of cancer (EORTC) guidelines. Eur J Cancer 49:1509–1510CrossRefPubMed
60.
go back to reference European Association for the Study of the Liver, European Organisation for Research and the Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943CrossRef European Association for the Study of the Liver, European Organisation for Research and the Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943CrossRef
61.
go back to reference Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRefPubMedPubMedCentral Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRefPubMedPubMedCentral
62.
go back to reference Kim CJ, Kim HJ, Park JH et al (2014) Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. Liver Int 34:305–312CrossRefPubMed Kim CJ, Kim HJ, Park JH et al (2014) Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. Liver Int 34:305–312CrossRefPubMed
63.
go back to reference Malagari K, Pomoni M, Kelekis A et al (2010) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33:541–551CrossRefPubMed Malagari K, Pomoni M, Kelekis A et al (2010) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33:541–551CrossRefPubMed
64.
go back to reference Facciorusso A, Licinio R, Muscatiello N et al (2015) Transarterial chemoembolization: evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol 7:2009–2019CrossRefPubMedPubMedCentral Facciorusso A, Licinio R, Muscatiello N et al (2015) Transarterial chemoembolization: evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol 7:2009–2019CrossRefPubMedPubMedCentral
65.
go back to reference Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739CrossRefPubMed Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739CrossRefPubMed
66.
go back to reference Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171CrossRefPubMed Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171CrossRefPubMed
67.
go back to reference Wong LL, Tanaka K, Lau L et al (2004) Pre-transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted livers. Clin Transpl 18:227–234CrossRef Wong LL, Tanaka K, Lau L et al (2004) Pre-transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted livers. Clin Transpl 18:227–234CrossRef
68.
go back to reference Graziadei IW, Sandmueller H, Waldenberger P et al (2003) Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 9:557–563CrossRefPubMed Graziadei IW, Sandmueller H, Waldenberger P et al (2003) Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 9:557–563CrossRefPubMed
69.
go back to reference Kamel IR, Bluemke DA, Ramsey D et al (2003) Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 181:708–710CrossRefPubMed Kamel IR, Bluemke DA, Ramsey D et al (2003) Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 181:708–710CrossRefPubMed
70.
71.
go back to reference Lesurtel M, Mullhaupt B, Pestalozzi BC et al (2006) Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 6:2644–2650CrossRefPubMed Lesurtel M, Mullhaupt B, Pestalozzi BC et al (2006) Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 6:2644–2650CrossRefPubMed
72.
go back to reference Yan FH, Zhou KR, Cheng JM et al (2002) Role and limitation of FMPSPGR dynamic contrast scanning in the follow-up of patients with hepatocellular carcinoma treated by TACE. World J Gastroenterol 8:658–662CrossRefPubMedPubMedCentral Yan FH, Zhou KR, Cheng JM et al (2002) Role and limitation of FMPSPGR dynamic contrast scanning in the follow-up of patients with hepatocellular carcinoma treated by TACE. World J Gastroenterol 8:658–662CrossRefPubMedPubMedCentral
73.
go back to reference Bruix J, Llovet JM, Castells A et al (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27:1578–1583CrossRefPubMed Bruix J, Llovet JM, Castells A et al (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27:1578–1583CrossRefPubMed
74.
go back to reference Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442CrossRefPubMed Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442CrossRefPubMed
75.
go back to reference Chapman WC, Majella Doyle MB, Stuart JE et al (2008) Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 248:617–625PubMed Chapman WC, Majella Doyle MB, Stuart JE et al (2008) Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 248:617–625PubMed
76.
go back to reference Roayaie S, Frischer JS, Emre SH et al (2002) Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235:533–539CrossRefPubMedPubMedCentral Roayaie S, Frischer JS, Emre SH et al (2002) Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235:533–539CrossRefPubMedPubMedCentral
77.
go back to reference De Luna W, Sze DY, Ahmed A et al (2009) Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant 9:1158–1168CrossRefPubMed De Luna W, Sze DY, Ahmed A et al (2009) Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant 9:1158–1168CrossRefPubMed
78.
go back to reference Gerber DA, Arcement C, Carr B et al (2000) Use of intrahepatic chemotherapy to treat advanced pediatric hepatic malignancies. J Pediatr Gastr Nutr 30:137–144CrossRef Gerber DA, Arcement C, Carr B et al (2000) Use of intrahepatic chemotherapy to treat advanced pediatric hepatic malignancies. J Pediatr Gastr Nutr 30:137–144CrossRef
79.
go back to reference Arcement CM, Towbin RB, Meza MP et al (2000) Intrahepatic chemoembolization in unresectable pediatric liver malignancies. Pediatr Radiol 30:779–785CrossRefPubMed Arcement CM, Towbin RB, Meza MP et al (2000) Intrahepatic chemoembolization in unresectable pediatric liver malignancies. Pediatr Radiol 30:779–785CrossRefPubMed
80.
go back to reference Malogolowkin MH, Stanley P, Steele DA et al (2000) Feasibility and toxicity of chemoembolization for children with liver tumors. J Clin Oncol 18:1279–1284CrossRefPubMed Malogolowkin MH, Stanley P, Steele DA et al (2000) Feasibility and toxicity of chemoembolization for children with liver tumors. J Clin Oncol 18:1279–1284CrossRefPubMed
81.
go back to reference Kennedy AS, Nutting C, Coldwell D et al (2004) Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60:1552–1563CrossRefPubMed Kennedy AS, Nutting C, Coldwell D et al (2004) Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60:1552–1563CrossRefPubMed
82.
go back to reference Chen JH, Chai JW, Huang CL et al (1999) Proximal arterioportal shunting associated with hepatocellular carcinoma: features revealed by dynamic helical CT. AJR Am J Roentgenol 172:403–407CrossRefPubMed Chen JH, Chai JW, Huang CL et al (1999) Proximal arterioportal shunting associated with hepatocellular carcinoma: features revealed by dynamic helical CT. AJR Am J Roentgenol 172:403–407CrossRefPubMed
83.
go back to reference Ho S, Lau WY, Leung TW et al (1996) Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med 23:947–952CrossRefPubMed Ho S, Lau WY, Leung TW et al (1996) Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med 23:947–952CrossRefPubMed
84.
go back to reference Liu DM, Salem R, Bui JT et al (2005) Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 16:911–935CrossRefPubMed Liu DM, Salem R, Bui JT et al (2005) Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 16:911–935CrossRefPubMed
86.
go back to reference Salem R, Lewandowski RJ, Kulik L et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497–507CrossRefPubMed Salem R, Lewandowski RJ, Kulik L et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497–507CrossRefPubMed
87.
go back to reference Hawkins CM, Kukreja K, Geller JI et al (2013) Radioembolisation for treatment of pediatric hepatocellular carcinoma. Pediatr Radiol 43:876–881CrossRefPubMed Hawkins CM, Kukreja K, Geller JI et al (2013) Radioembolisation for treatment of pediatric hepatocellular carcinoma. Pediatr Radiol 43:876–881CrossRefPubMed
88.
go back to reference Li CP, Chao Y, Chen LT et al (2008) Fever after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. Scand J Gastroenterol 43:992–999CrossRefPubMed Li CP, Chao Y, Chen LT et al (2008) Fever after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. Scand J Gastroenterol 43:992–999CrossRefPubMed
89.
go back to reference Bissler JJ, Racadio J, Donnelly LF et al (2002) Reduction of postembolization syndrome after ablation of renal angiomyolipoma. Am J Kidney Dis 39:966–971CrossRefPubMed Bissler JJ, Racadio J, Donnelly LF et al (2002) Reduction of postembolization syndrome after ablation of renal angiomyolipoma. Am J Kidney Dis 39:966–971CrossRefPubMed
Metadata
Title
Role of interventional radiology in managing pediatric liver tumors
Part 1: Endovascular interventions
Authors
Matthew P. Lungren
Alexander J. Towbin
Derek J. Roebuck
Eric J. Monroe
Anne E. Gill
Avnesh Thakor
Richard B. Towbin
Anne Marie Cahill
C. Matthew Hawkins
Publication date
01-04-2018
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Radiology / Issue 4/2018
Print ISSN: 0301-0449
Electronic ISSN: 1432-1998
DOI
https://doi.org/10.1007/s00247-018-4068-1

Other articles of this Issue 4/2018

Pediatric Radiology 4/2018 Go to the issue

Minisymposium: Fetal/neonatal imaging

Imaging of congenital central nervous system infections

Minisymposium: Fetal/neonatal imaging

Non-sedation of the neonate for radiologic procedures